The FDA approved the pill Nereus (tradipitant) as a new treatment for vomiting caused by motion sickness, with fewer side ...

For the first time in over 40 years, the Food and Drug Administration has approved a new treatment for motion sickness.

Does motion sickness turn you into a green, spewing mess? For plenty of people, the answer is yes. Current remedies may or ...

The Food and Drug Administration has approved Nereus (tradipitant) for the prevention of vomiting induced by motion in adults.

Analysts raise price targets for Vanda Pharmaceuticals after FDA approved a motion sickness drug, citing growth potential.

Millions of Americans can now look forward to a better time traveling, with the US Food and Drug Administration (FDA) approving a novel oral pill that helps prevent motion-induced vomiting – the first ...

Just days after scoring a big win from the FDA, a D.C. pharmaceutical company has learned that its years-long quest to market ...

The FDA's usual end-of-year flurry of regulatory approvals is a little lighter than usual, but the agency has delivered some end-of-year cheer to Vanda Pharma after giving the go-ahead to its drug for ...

The FDA delivered a pair of holiday season approvals a week apart, signing off on Agios’ oral medicine Aqvesme for the treatment of anemia in adults with alpha- or beta-thalassemia on Dec. 23, and ...

Vanda Pharmaceuticals has received FDA approval for Nereus (tradipitant), an oral NK-1 receptor antagonist developed to prevent motion-induced vomiting. The approval makes Nereus the first new ...

The FDA approved Vanda’s drug Nereus to prevent motion-induced vomiting, opening a potential path into treating nausea linked to GLP-1 weight-loss drugs.

In today’s ACT Brief, we explore how site initiation can be leveraged to improve early trial performance through demonstrated ...